CGI vs Cognizant

CGI named a Leader in the 2026 IDC MarketScape vendor assessment of worldwide trade finance systems

CGI has been named a Leader in the 2026 IDC MarketScape vendor assessment of worldwide trade finance systems, a significant industry recognition for the company's trade finance technology leadership.

10-Q Financial Filing Analysis for CGI (2026-07-29)

Corcept Therapeutics reported strong financial results for the second quarter ended June 30, 2026, generating net product revenue of $256.1 million, a 31.7% increase year-over-year. Growth was accelerated by the commercial launch of Lifyorli (relacorilant) in combination with nab-paclitaxel for platinum-resistant ovarian cancer, which contributed $47.6 million in debut quarterly sales alongside core hypercortisolism therapies. On the regulatory and legal front, Corcept resubmitted its relacorilant NDA for endogenous Cushing's syndrome with a PDUFA date set for December 17, 2026, while the Court of Appeals affirmed a non-infringement ruling in the Teva patent litigation and denied a rehearing en banc in July 2026.

• Q2 2026 net product revenue rose 31.7% year-over-year to $256.1 million, bolstered by $47.6 million in initial sales from newly launched Lifyorli.
• Corcept resubmitted its New Drug Application (NDA) for relacorilant in endogenous Cushing's syndrome on June 17, 2026, establishing an FDA PDUFA target action date of December 17, 2026.
• The Court of Appeals affirmed a District Court ruling of non-infringement in the Teva patent litigation, with a petition for rehearing en banc denied in July 2026.

CGI Prices C$500 Million Senior Notes Offering

CGI Inc. has priced a private offering of C$500 million in senior unsecured notes, split equally between 3.25-year and 4.75-year maturities, with interest rates of 4.195% and 4.484% respectively. The offering is expected to close around September 14, 2026, and the net proceeds of approximately C$497.3 million will be used to repay existing indebtedness and for general corporate purposes. The notes are being offered in Canada on a private placement basis through a syndicate of agents led by major Canadian financial institutions including Scotiabank, Desjardins, BMO, CIBC, National Bank, RBC, and TD Securities. This financing move is part of CGI's capital management strategy to optimize its debt structure, reflecting the company's strong market position and liquidity management.

• CGI priced C$500 million in senior unsecured notes, split into two series of C$250 million each.
• The notes carry interest rates of 4.195% (3.25-year) and 4.484% (4.75-year).
• Net proceeds of ~C$497.3 million will be used for debt repayment and general corporate purposes.

10-Q Financial Filing Analysis for Cognizant (2026-07-29)

Cognizant Technology Solutions reported financial results for Q2 2026, delivering quarterly revenues of $5.48 billion, representing a 4.5% year-over-year increase (4.1% in constant currency). Revenue expansion was supported by large deal ramp-ups, growing demand in AI, analytics, and intuitive operations, as well as inorganic contributions from recent acquisitions including 3Cloud and Astreya Partners. Operating income grew 7.0% year-over-year to $874 million, yielding an operating margin of 15.9%, bolstered by operational efficiencies and foreign currency tailwinds, offset by compensation increases and dilution from acquisitions. During the quarter, Cognizant launched 'Project Leap', a multi-faceted restructuring initiative designed to accelerate AI-enabled delivery and optimize workforce productivity, incurring $84 million in restructuring charges with anticipated total program costs of $230 million to $320 million in 2026. This was counterbalanced by an $81 million reversal of an India Defined Contribution Obligation liability. The company also returned substantial capital to shareholders, repurchasing $1.15 billion in Class A common stock during the quarter.

• Q2 2026 revenues reached $5,481 million, up 4.5% YoY (4.1% constant currency), driven by strong Financial Services growth of 12.0% YoY to $1,733 million.
• GAAP operating income increased to $874 million (15.9% margin), impacted by $84 million in Project Leap restructuring costs and an offsetting $81 million SG&A benefit from the reversal of an Indian labor obligation liability.
• Capital allocation remained aggressive with $1.153 billion deployed into share repurchases in Q2 ($500 million via ASR) and completion of the Astreya acquisition for $634 million net of cash acquired, supported by drawing $1.0 billion on the revolving credit facility.

Cognizant and Cognition put autonomous AI engineering into production at Odyssey Logistics, with a 37 percent net cost saving

Cognizant and Cognition have deployed autonomous AI engineering at Odyssey Logistics, achieving a 37 percent net cost saving. This marks a significant production deployment of autonomous AI in logistics.

Copado Launches Agentia Headless for Governed Salesforce AgentOps

Copado announced Agentia Headless, a new developer experience that integrates governed AI agents directly into the IDE and terminal, allowing Salesforce developers to operate Copado pipelines, trigger tests, and enforce governance without switching tools. Part of the Agentia by Copado platform, it addresses bottlenecks in testing and deploying AI-generated code, claiming up to 70% faster releases and reduced production defects. The tool is aimed at organizations running Agentforce, Agentforce Revenue Management, and Data 360. Quotes from CEO Ted Elliott and a Cognizant consultant highlight its enterprise relevance.

• Copado announced Agentia Headless, a developer experience for governed AI agents within IDEs and terminals.
• Agentia Headless is part of the Agentia by Copado platform, announced earlier.
• The tool enables AI agents to act as pipeline operators, executing plans, tests, commits, and deployments.